Mymetics Corp (MYMX)

[FALCON1]

Copy of MACIVIVA Presentation at World Vaccine Congress 10th-12th Oct.2017 in Barcelona, Spain is now uploaded (downloadable) in company website!

https://www.mymetics.com/media-center/world-vaccine-congress-10-12-october-2017-barcelona/

Conclusions:
? Pilot lines were developed - optimization ongoing
? Intranasal spray powder preserved virosome immunogenicity
v Serum antibodies
v Nasal antibodies
v Vaginal antibodies
v Rectal antibodies (not shown)
? Adjuvant improves the nasal powder vaccine-induced antibodies
? Preliminary results with oral capsules and sublingual tablets with
virosomal HIV-1 vaccines: Preservation of virosomes and antigens
confirmed (data not shown). Vaccine delivery conditions need to be
further optimized.
Serum > Nasal > Vaginal > Rectal



Progress looks good!


regards